金额单位：万元 项 目 序号 金 额 募集资金净额 A 178,026.23 截至期初（2024.12.31） 项目投入 B1 40,664.60 项 目 序号 金 额 累计发生额 利息收入净额 C1 674.98 项目投入 B2 3,641.62 本期发生额 利息收入净额 C2 148.59 截至期末（2025.6.30） 项目投入 B3=B1+B2 44,306.22 累计发生额 利息收入净额 C3=C1+C2 823.57 应结余募集资金 D=A-B3+C3 134,543.58 实际结余募集资金 E 13,363.58 差异 F=D-E 121,180.00 [注 1]上表中应结余募集资金金额与实际结余募集资金的差异来源是：(1) 公司使用部 分闲置募集资金暂时补充流动资金 110,000.00 万元；(2) 募集资金报告期末未到期理财 [注 2]数据若存在尾差，为四舍五入所致。 二、募集资金管理情况 (一) 募集资金管理情况 为了规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权 益，本公司按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司监管指引第 2 号——上市公司募集 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [1][6]. Core Views - The company reported a total revenue of 11.722 billion yuan for the first half of 2025, a slight decrease of 0.34% year-on-year, while the net profit attributable to shareholders increased by 10.32% year-on-year to 880 million yuan, aligning with expectations [1]. - The decline in revenue is attributed to the closure of some stores and a slowdown in new store expansion, while the increase in net profit is due to cost reduction and efficiency improvements [3]. - The company aims to consolidate its presence in Central South, East China, and North China while expanding nationally, with a focus on a multi-tiered store network [3]. - The company has continued to develop its online business, achieving a total sales revenue of 1.355 billion yuan from internet operations in the first half of 2025, with O2O sales contributing 944 million yuan and B2C sales contributing 411 million yuan [3]. - The gross margin improved by 0.42 percentage points to 40.47%, and the net profit margin increased by 0.76 percentage points to 8.07%, benefiting from cost reduction and efficiency improvements [3]. Summary by Sections Financial Performance - For the first half of 2025, the company achieved total revenue of 11.722 billion yuan and a net profit of 880 million yuan, with respective year-on-year changes of -0.34% and +10.32% [1]. - The company’s total number of stores reached 14,701, including 10,681 direct-operated stores and 4,020 franchise stores [3]. Future Projections - The company forecasts earnings per share of 1.45 yuan and 1.69 yuan for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 17 times and 14 times, indicating that the current valuation is at a historical low for the past decade [3][4].

Core Insights - Yifeng Pharmacy (603939.SH) reported a total operating revenue of 11.722 billion yuan for the first half of 2025, a decrease of 40.5815 million yuan compared to the same period last year, representing a year-on-year decline of 0.35% [1] - The net profit attributable to shareholders was 880 million yuan, while the net cash inflow from operating activities was 1.57 billion yuan, down 252 million yuan from the same period last year, reflecting a year-on-year decrease of 13.84% [1] Financial Metrics - The latest debt-to-asset ratio stands at 54.84% [3] - The latest gross profit margin is 40.47%, and the return on equity (ROE) is 7.89% [4] - The diluted earnings per share (EPS) is 0.73 yuan [4] - The total asset turnover ratio is 0.43 times, ranking 18th among disclosed peers, a decrease of 0.03 times year-on-year, which is a decline of 7.18% [4] - The inventory turnover ratio is 1.59 times, ranking 21st among disclosed peers, down 0.27 times year-on-year, reflecting a decline of 14.43% [4] Shareholder Structure - The number of shareholders is 21,600, with the top eight shareholders holding a total of 683 million shares, accounting for 56.30% of the total share capital [4] - The top shareholders include: 1. Ningbo Meishan Free Trade Port Area Houxin Venture Capital Partnership (Limited Partnership) - 21.6% 2. Hong Kong Central Clearing Limited - 19.5% 3. Gao Yi - 11.6% 4. Ningbo Meishan Free Trade Port Area Yizhi Feng Enterprise Management Partnership (Limited Partnership) - 1.05% 5. Agricultural Bank of China Co., Ltd. - CSI 500 ETF - 0.74% 6. Industrial and Commercial Bank of China Co., Ltd. - China Europe Medical Health Mixed Securities Investment Fund - 0.64% 7. Han Hongchang - 0.50% 8. Ningbo Meishan Free Trade Port Area Yirentang Enterprise Management Partnership (Limited Partnership) - 0.48% [4]

Core Viewpoint - The company reported a net profit of 880,045,883.20 yuan for the first half of 2025, with a proposed cash dividend of 0.30 yuan per share, amounting to a total distribution of 363,725,056.20 yuan, which represents 41.33% of the net profit attributable to shareholders [4][30]. Group 1: Financial Performance - The company achieved a net profit of 880,045,883.20 yuan for the first half of 2025 [4]. - The total profit available for distribution to shareholders at the end of the reporting period was 5,761,758,753.44 yuan [4]. - The proposed cash dividend is 0.30 yuan per share, with an estimated total payout of 363,725,056.20 yuan [4][30]. Group 2: Store Network and Operations - As of June 30, 2025, the company operated 10,681 directly managed stores, with 95.37% of these stores having obtained medical insurance qualification [6][9]. - The company continues to expand its store network, with a total of 14,701 stores (including 4,020 franchise stores) and a total operating area of 1,064,700 square meters [8]. - The company closed 272 stores during the reporting period, primarily due to location optimization and strategic adjustments [6]. Group 3: Online Business Development - The company has built a new retail ecosystem focusing on member services, big data, and online healthcare, achieving online sales revenue of 1,355 million yuan during the reporting period [7]. - The membership base reached 110 million, with member sales accounting for 84.93% of total sales [7]. Group 4: Fundraising and Usage - The company raised 1,797.432 million yuan through the issuance of convertible bonds, with a net amount of 1,780.026 million yuan after deducting fees [10][11]. - The company has established 22 special accounts for the management of raised funds, ensuring compliance with regulatory requirements [12].

Group 1 - The company Yifeng Pharmacy announced the approval of multiple proposals, including the agenda for the 2025 semi-annual report and its summary, during the 21st meeting of the fifth board of directors held on August 28 [2]

Core Viewpoint - Yifeng Pharmacy reported a slight decline in revenue for the first half of the year, but a significant increase in net profit, indicating effective cost management and strategic adjustments in response to market conditions [1] Financial Performance - The company achieved operating revenue of 11.722 billion yuan, a year-on-year decrease of 0.35% [1] - The net profit attributable to shareholders was 880 million yuan, reflecting a year-on-year growth of 10.32% [1] Strategic Adjustments - The decline in revenue is attributed to the strategic decision to close some stores and slow down the expansion of new stores in response to industry and economic conditions [1] - Despite the revenue decline, the company's profitability improved due to cost-cutting measures and operational efficiency enhancements [1]

Core Insights - In the first half of 2025, the company reported a revenue of 11.722 billion yuan, a slight decrease of 0.35% year-on-year, while the net profit attributable to shareholders increased by 10.32% to 880 million yuan [1][2] Group 1: Financial Performance - The revenue decline is attributed to strategic adjustments, including the closure of some stores and a slowdown in new store openings [1] - The net profit growth indicates improved profitability through cost reduction and operational efficiency [1] Group 2: Business Operations - The company operates 10,700 direct stores, with 9,717 being small community stores, and 10,200 stores have obtained various "medical insurance designated retail pharmacy" qualifications, representing 95.37% of the total [2] - The total number of registered members reached 110 million, with member sales accounting for 84.93% of total sales [2] - The company's internet business generated a sales revenue of 1.355 billion yuan during the reporting period, with O2O sales contributing 944 million yuan and B2C sales contributing 411 million yuan [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意益丰大药房连锁股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕109 号），本公 司由主承销商中信证券股份有限公司采用余额包销方式，向社会公众公开发行可 转换公司债券 1,797.4320 万张，每张面值为人民币 100.00 元，按面值发行，共 计募集资金 179,743.20 万元，坐扣承销和保荐费用 1,350.00 万元(含税）后的募 集资金为 178,393.20 万元，已由主承销商中信证券股份有限公司于 2024 年 3 月 8 日汇入本公司募集资金监管账户。另减除上网发行费、招股说明书印刷费、申 报会计师费、律师费、评估费等与发行权益性证券直接相关的新增外部费用 469.99 万元，加上发行费用中可抵扣的增值税进项税人民币 103.02 万元后，公 司本次募集资金净额为 178,026.23 万元。上述募集资金到位情况业经天健会计师 ...

证券代码:603939 证券简称:益丰药房 公告编号:2025-081 债券代码:113682 债券简称:益丰转债 益丰大药房连锁股份有限公司 关于2025年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年半年度报告披露工作的通知》相关要求，现将益丰大药房连锁 股份有限公司（以下简称"公司"）2025 年半年度主要经营数据披露如下： 一、报告期末主要经营数据 1、主要会计数据 单位：元 币种：人民币 | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上 年同期增减 | | --- | --- | --- | --- | | | （1－6月） | | | | | | | (%) | | 营业收入 | 11,721,819,634.46 | 11,762,401,111.51 | -0.35 | | 归属于上市公司股东的净利润 | 880,045,883.20 | 797,718,135.20 | 1 ...

智通财经APP讯，益丰药房(603939.SH)发布2025年半年度报告，报告期内，公司实现营业收入117.22亿 元，同比下降0.35%。实现归属于上市公司股东的净利润8.8亿元，同比增长10.32%。实现归属于上市公 司股东的扣除非经常性损益的净利润8.57亿元，同比增长9.08%。基本每股收益0.73元。 ...